MX342553B - Metodos para monitorear la modulacion de la actividad de cinasa del receptor del factor de crecimiento de fibroblastos y uso de dichos metodos. - Google Patents

Metodos para monitorear la modulacion de la actividad de cinasa del receptor del factor de crecimiento de fibroblastos y uso de dichos metodos.

Info

Publication number
MX342553B
MX342553B MX2013009814A MX2013009814A MX342553B MX 342553 B MX342553 B MX 342553B MX 2013009814 A MX2013009814 A MX 2013009814A MX 2013009814 A MX2013009814 A MX 2013009814A MX 342553 B MX342553 B MX 342553B
Authority
MX
Mexico
Prior art keywords
methods
growth factor
fibroblast growth
modulation
kinase activity
Prior art date
Application number
MX2013009814A
Other languages
English (en)
Inventor
Graus Porta Diana
Guagnano Vito
Marrer Estelle
Verdes Pablo
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX342553B publication Critical patent/MX342553B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere al uso de fósforo inorgánico (P) como un biomarcador para monitorear la inhibición de la actividad de cinasa de receptor del factor de crecimiento de fibroblastos (FGFR) y/o uno o más efectos secundarios de un inhibidor de FGFR. Un método ex vivo para determinar la inhibición de la actividad de cinasa del FGFR que comprende los pasos de: a) determinar el nivel de fósforo inorgánico (P) en una muestra de un paciente antes del inicio de un tratamiento con un inhibidor FGFR (nivel de referencia individual); en donde el nivel de fósforo inorgánico (P) elevado del paso b) con respecto al nivel de referencia individual indica la inhibición de la actividad de cinasa de FGFR ocurrida.
MX2013009814A 2008-04-29 2009-04-28 Metodos para monitorear la modulacion de la actividad de cinasa del receptor del factor de crecimiento de fibroblastos y uso de dichos metodos. MX342553B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08155401 2008-04-29
EP08156856 2008-05-23
PCT/EP2009/055127 WO2009133101A1 (en) 2008-04-29 2009-04-28 Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods

Publications (1)

Publication Number Publication Date
MX342553B true MX342553B (es) 2016-10-04

Family

ID=40792814

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013009814A MX342553B (es) 2008-04-29 2009-04-28 Metodos para monitorear la modulacion de la actividad de cinasa del receptor del factor de crecimiento de fibroblastos y uso de dichos metodos.
MX2010011959A MX2010011959A (es) 2008-04-29 2009-04-28 Metodos para monitorear la modulacion de la actividad de cinasa del receptor del factor de crecimiento de fibroblastos y uso de dichos metodos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2010011959A MX2010011959A (es) 2008-04-29 2009-04-28 Metodos para monitorear la modulacion de la actividad de cinasa del receptor del factor de crecimiento de fibroblastos y uso de dichos metodos.

Country Status (16)

Country Link
US (2) US20110045511A1 (es)
EP (1) EP2271943A1 (es)
JP (3) JP5539963B2 (es)
KR (1) KR101660544B1 (es)
CN (2) CN102016592A (es)
BR (1) BRPI0911491A2 (es)
CA (1) CA2720888A1 (es)
IL (2) IL208725A (es)
MA (1) MA32364B1 (es)
MX (2) MX342553B (es)
NZ (1) NZ609066A (es)
RU (2) RU2010148531A (es)
SG (1) SG190592A1 (es)
TW (1) TWI526687B (es)
WO (1) WO2009133101A1 (es)
ZA (1) ZA201007119B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
EP2512476A1 (en) * 2009-12-18 2012-10-24 Novartis AG Method for treating haematological cancers
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
JP2014513930A (ja) * 2011-03-17 2014-06-19 ノバルティス アーゲー Ｈｒ陽性対象における乳がんのバイオマーカーとしてのｆｇｆｒおよびそのリガンド
US20130136740A1 (en) * 2011-11-14 2013-05-30 Thomas Harding Methods of treating cancer
MX354783B (es) * 2012-03-30 2018-03-21 Novartis Ag Inhibidor de fgfr para su uso en el tratamiento de trastornos hipofosfatemicos.
KR20140146086A (ko) * 2012-04-03 2014-12-24 노파르티스 아게 티로신 키나제 억제제 조합물 및 그의 용도
CN107383009B (zh) 2012-06-13 2020-06-09 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SG11201508328PA (en) 2013-04-19 2015-11-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CN107438607B (zh) 2015-02-20 2021-02-05 因赛特公司 作为fgfr抑制剂的双环杂环
CL2015003047A1 (es) * 2015-10-15 2016-06-17 Univ Chile Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina
RU2634573C1 (ru) * 2016-07-05 2017-10-31 государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ стратификации риска поражения сердечно-сосудистой системы у пациентов с хронической болезнью почек
JOP20190080A1 (ar) * 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
AU2019262195B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2022552324A (ja) 2019-10-14 2022-12-15 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての二環式複素環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7416856B2 (en) * 1999-05-18 2008-08-26 Cytokinetics, Inc. High sensitivity assay for detection of nucleoside diphosphate production
CA2398603A1 (en) * 2000-02-15 2001-08-23 Amgen, Inc. Fibroblast growth factor-23 molecules and uses thereof
JP2002014095A (ja) * 2000-06-30 2002-01-18 Srl Inc 血液検査データ解析及び表示システム並びに方法
KR20090036151A (ko) * 2000-07-19 2009-04-13 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 신규 섬유아세포 성장 인자 (ｆｇｆ23) 및 그의 이용 방법
GB0023080D0 (en) * 2000-09-20 2000-11-01 Univ Liverpool Prognostic indicator
US20050004348A1 (en) * 2002-12-23 2005-01-06 Miyamoto Ken-Ichi Novel type II Na/Pi cotransporters and type II Na/Pi cotransporter expression regulatory factors
US7259144B2 (en) * 2003-02-21 2007-08-21 Curagen Corporation Methods for diagnosing and treatment of hyperphosphatemic conditions using FGF20 polypeptides
WO2004083381A2 (en) * 2003-03-13 2004-09-30 Indiana University Advanced Research & Technology Institute Fibroblast growth factor receptor-1 polynucleotides, polypeptides, and mutants
US7078528B2 (en) * 2003-07-02 2006-07-18 East Carolina University Biimidazole diamide anion binding agents
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
RU2008127252A (ru) * 2005-12-08 2010-01-20 Новартис АГ (CH) Эффекты ингибиторов fgfr3 на транскрипцию генов
JP2007178356A (ja) * 2005-12-28 2007-07-12 Japan Health Science Foundation 骨質を評価する方法，骨質の評価キット，骨質劣化予防又は改善剤のスクリーニング方法，及び骨質劣化予防又は改善剤のスクリーニング用キット
JP2008017790A (ja) * 2006-07-14 2008-01-31 Hiroshima Univ 石灰化調節剤及びそのスクリーニング法
DE102007026877A1 (de) * 2007-06-08 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Verwendung des Fibroblastenwachstumsfaktors 7 (Fgf7) und des Rezeptors Fgfr2b als Biomarker
WO2009091556A2 (en) * 2008-01-17 2009-07-23 The General Hospital Corporation Diagnostic methods and kits using fibroblast growth factor-23

Also Published As

Publication number Publication date
RU2013131640A (ru) 2015-01-20
WO2009133101A1 (en) 2009-11-05
US20150323548A1 (en) 2015-11-12
KR20100135956A (ko) 2010-12-27
US20110045511A1 (en) 2011-02-24
IL208725A0 (en) 2010-12-30
JP2014142349A (ja) 2014-08-07
CN102016592A (zh) 2011-04-13
JP2011519043A (ja) 2011-06-30
KR101660544B1 (ko) 2016-09-27
IL229822A0 (en) 2014-01-30
IL208725A (en) 2014-06-30
TW200949247A (en) 2009-12-01
EP2271943A1 (en) 2011-01-12
CN103353532A (zh) 2013-10-16
TWI526687B (zh) 2016-03-21
MX2010011959A (es) 2010-11-30
JP2015172584A (ja) 2015-10-01
MA32364B1 (fr) 2011-06-01
IL229822A (en) 2016-02-29
SG190592A1 (en) 2013-06-28
RU2010148531A (ru) 2012-06-10
ZA201007119B (en) 2016-02-24
CN103353532B (zh) 2016-05-11
NZ609066A (en) 2014-07-25
AU2009242176A1 (en) 2009-11-05
CA2720888A1 (en) 2009-11-05
BRPI0911491A2 (pt) 2016-01-05
JP5539963B2 (ja) 2014-07-02

Similar Documents

Publication Publication Date Title
MX342553B (es) Metodos para monitorear la modulacion de la actividad de cinasa del receptor del factor de crecimiento de fibroblastos y uso de dichos metodos.
WO2007146165A3 (en) Bone plates with intraoperatively tapped apertures
MY146989A (en) Kinase inhibitors
WO2015002724A4 (en) SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
CA2755394C (en) Methods and compositions for cell-proliferation-related disorders
WO2011137292A3 (en) Injectable, load-bearing cell/microbead/calcium phosphate bone paste for bone tissue engineering
GB2419096A (en) Bone plates with intraoperatively tapped apertures
WO2010033906A3 (en) Efficient induction of pluripotent stem cells using small molecule compounds
MX366127B (es) Composiciones de pretratamiento de zirconio que contienen molibdeno, metodos asociados para tratar sustratos metalicos, y sustratos metalicos revestidos relacionados.
MY180473A (en) Imaging and evaluating embryos, oocytes, and stem cells
HK1123294A1 (en) Pyrazolopyrimidine derivatives for use as kinase antagonists
WO2007117995A3 (en) Kinase inhibitors
HK1141841A1 (en) Pretreatment compositions and methods for coating a metal substrate
WO2009079412A3 (en) Reverse transcriptase inhibitors
MX2009007564A (es) Composiciones y metodos para diagnosticar, tratar, y prevenir afecciones de la prostata.
BR112012014925A2 (pt) compostos promotores de replicação de células beta e métodos de uso dos mesmos
WO2005105984A3 (en) Culture conditions and growth factors affecting fate determination, self-renewal and expansion of mouse spermatogonial stem cells
MX2009006151A (es) Dispersiones de poliuretano de auto-entrelazamiento y libres de cosolventes.
MY150212A (en) Methods for treating a ferrous metal substrate
MX2011013451A (es) Nuevo compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias.
EP2083593A3 (en) Controlling spectrum use
SG150456A1 (en) Lubricant compositions with reduced phosphorous content for engines having catalytic converters
TN2009000151A1 (en) Mapk/erk kinase inhibitors
MY169256A (en) Zirconium pretreatment compositions containing lithium, associated methods for treating metal substrates, and related coated metal substrates
WO2012062819A3 (en) Method for controlling binding of cells to a substrate